Harmony Biosciences Holdings, Inc.
EPX-100
Dravet Syndrome (DS)
Countdown
178days
Phase 3 readout · ~ Jan 1, 2027 estimated
What's at stake
Phase 3 trial results for EPX-100 in Dravet Syndrome (DS) are due ~ Jan 1, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Topline data anticipated in 1H 2027”